BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 1349039)

  • 1. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide.
    Krenning EP; Bakker WH; Kooij PP; Breeman WA; Oei HY; de Jong M; Reubi JC; Visser TJ; Bruns C; Kwekkeboom DJ
    J Nucl Med; 1992 May; 33(5):652-8. PubMed ID: 1349039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo studies of three radiolabelled somatostatin analogues: 123I-octreotide (OCT), 123I-Tyr-3-OCT and 111In-DTPA-D-Phe-1-OCT.
    Virgolini I; Angelberger P; Li S; Yang Q; Kurtaran A; Raderer M; Neuhold N; Kaserer K; Leimer M; Peck-Radosavljevic M; Scheithauer W; Niederle B; Eichler HG; Valent P
    Eur J Nucl Med; 1996 Oct; 23(10):1388-99. PubMed ID: 8781146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.
    Hofland LJ; Lamberts SW; van Hagen PM; Reubi JC; Schaeffer J; Waaijers M; van Koetsveld PM; Srinivasan A; Krenning EP; Breeman WA
    J Nucl Med; 2003 Aug; 44(8):1315-21. PubMed ID: 12902423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
    Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F
    Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation.
    Bakker WH; Albert R; Bruns C; Breeman WA; Hofland LJ; Marbach P; Pless J; Pralet D; Stolz B; Koper JW
    Life Sci; 1991; 49(22):1583-91. PubMed ID: 1658515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
    Boni G; Ferdeghini M; Bellina CR; Matteucci F; Castro Lopez E; Parenti G; Canapicchi R; Bianchi R
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution and dosimetry of 111In DTPA-D-Phe-octreotide in man assessed by whole body scintigraphy.
    Bajc M; Palmer J; Ohlsson T; Edenbrandt L
    Acta Radiol; 1994 Jan; 35(1):53-7. PubMed ID: 8305273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical evaluation of safety, pharmacokinetics and dosimetry of the somatostatin analog 111In-DTPA-D-Phe-octreotide--report of the phase 1 study].
    Inoue T; Ootake H; Hirano T; Tomiyoshi K; Endo K; Tanaka K; Shimizu N; Saito T
    Kaku Igaku; 1995 May; 32(5):511-21. PubMed ID: 7596072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats.
    Bakker WH; Krenning EP; Reubi JC; Breeman WA; Setyono-Han B; de Jong M; Kooij PP; Bruns C; van Hagen PM; Marbach P
    Life Sci; 1991; 49(22):1593-601. PubMed ID: 1658516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide.
    Breeman WA; Hofland LJ; van der Pluijm M; van Koetsveld PM; de Jong M; Setyono-Han B; Bakker WH; Kwekkeboom DJ; Visser TJ; Lamberts SW
    Eur J Nucl Med; 1994 Apr; 21(4):328-35. PubMed ID: 7911760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide.
    Meisetschläger G; Poethko T; Stahl A; Wolf I; Scheidhauer K; Schottelius M; Herz M; Wester HJ; Schwaiger M
    J Nucl Med; 2006 Apr; 47(4):566-73. PubMed ID: 16595488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide.
    Förster GJ; Engelbach MJ; Brockmann JJ; Reber HJ; Buchholz HG; Mäcke HR; Rösch FR; Herzog HR; Bartenstein PR
    Eur J Nucl Med; 2001 Dec; 28(12):1743-50. PubMed ID: 11734910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients.
    Virgolini I; Szilvasi I; Kurtaran A; Angelberger P; Raderer M; Havlik E; Vorbeck F; Bischof C; Leimer M; Dorner G; Kletter K; Niederle B; Scheithauer W; Smith-Jones P
    J Nucl Med; 1998 Nov; 39(11):1928-36. PubMed ID: 9829585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
    Kwekkeboom DJ; Kooij PP; Bakker WH; Mäcke HR; Krenning EP
    J Nucl Med; 1999 May; 40(5):762-7. PubMed ID: 10319747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo use of a radioiodinated somatostatin analogue: dynamics, metabolism, and binding to somatostatin receptor-positive tumors in man.
    Bakker WH; Krenning EP; Breeman WA; Kooij PP; Reubi JC; Koper JW; de Jong M; Laméris JS; Visser TJ; Lamberts SW
    J Nucl Med; 1991 Jun; 32(6):1184-9. PubMed ID: 1646302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors.
    Janson ET; Westlin JE; Ohrvall U; Oberg K; Lukinius A
    J Nucl Med; 2000 Sep; 41(9):1514-8. PubMed ID: 10994731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin receptor scintigraphy using [111In-DTPA0]RC-160 in humans: a comparison with [111In-DTPA0]octreotide.
    Breeman WA; van Hagen PM; Kwekkeboom DJ; Visser TJ; Krenning EP
    Eur J Nucl Med; 1998 Feb; 25(2):182-6. PubMed ID: 9473268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.
    Bangard M; Béhé M; Guhlke S; Otte R; Bender H; Maecke HR; Biersack HJ
    Eur J Nucl Med; 2000 Jun; 27(6):628-37. PubMed ID: 10901448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo evaluation of copper-64-octreotide conjugates.
    Anderson CJ; Pajeau TS; Edwards WB; Sherman EL; Rogers BE; Welch MJ
    J Nucl Med; 1995 Dec; 36(12):2315-25. PubMed ID: 8523125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide.
    Ur E; Bomanji J; Mather SJ; Britton KE; Wass JA; Grossman AB; Besser GM
    Clin Endocrinol (Oxf); 1993 May; 38(5):501-6. PubMed ID: 8101146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.